
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio Inc. is advancing its innovative portfolio of RNA editing therapies, with specific attention to KRRO-121, an RNA editing drug targeting liver conditions that demonstrates enhanced ammonia clearance, suggesting a significant potential to address unmet medical needs in this sector. The promising preclinical data from both mouse and non-human primate models indicates a robust safety profile and effective intervention, with blockbuster market potentials of approximately $1.5 billion and $2.0 billion for related diseases. Additionally, the company's upcoming IND filing for KRRO-121, scheduled for the second half of 2026, aligns with a clear regulatory pathway, enhancing confidence in Korro Bio’s future growth and valuation.
Bears say
Korro Bio Inc has recently faced significant challenges, highlighted by the negative results from its KRRO-110 program, which led to a notable selloff of its stock and casts doubt on the future of its pipeline. Key risks associated with the company's operations include potential delays in clinical trials, the possibility of unfavorable clinical data from ongoing programs like KRRO-121, and concerns regarding long-term dilution risk for shareholders. Furthermore, the regulatory landscape presents additional uncertainties, as disagreements with authorities such as the FDA and EMA on data interpretations could further hinder the company's progress and market competitiveness.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares